eligibility_summary
Key eligibility: non-squamous stage IIIB/C–IV NSCLC not curable by surgery/definitive CRT, no EGFR/ALK/ROS1 or other targetable alterations, PD-L1 ≥50%, measurable lesion, ECOG 0–1, adequate organs, tumor tissue required. Excludes prior systemic therapy, squamous/mixed histology, recent cancer, autoimmune disease, uncontrolled illness incl ILD/pneumonitis, non-drainable effusion, pulmonary compromise, untreated/unstable CNS mets, leptomeningeal, corneal disease, active TB/HBV/HCV/HAV or uncontrolled HIV, primary immunodeficiency.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase III, first-line NSCLC trial compares: 1) Datopotamab deruxtecan (Dato‑DXd) + rilvegostomig, 2) Rilvegostomig alone, vs 3) Pembrolizumab alone. Drugs/mechanisms: - Datopotamab deruxtecan: TROP2‑directed antibody–drug conjugate, internalizes into TROP2+ tumor cells to deliver a topoisomerase I inhibitor (DXd), causing DNA damage and tumor cell death. - Rilvegostomig (AZD2936): bispecific immune checkpoint antibody targeting PD‑1 and TIGIT to reinvigorate T cells and NK cells. - Pembrolizumab: anti‑PD‑1 monoclonal antibody checkpoint inhibitor. Cells/pathways targeted: TROP2‑expressing tumor cells, PD‑1 on T cells, TIGIT on T and NK cells. Pathways: PD‑1/PD‑L1 and TIGIT/CD155 (NECTIN) inhibitory axes, topo I–mediated DNA replication/repair in tumor cells.